Teva Settles Generic Drug Price-Fixing Case After a Decade - US News Pulse
Teva Pharmaceutical Industries has agreed to settle a sweeping lawsuit brought by 45 US states that accused the drugmaker of conspiring to fix the prices of dozens of generic medicines, bringing a decade of litigation over alleged collusion in the generic drug market close to an end. A federal judge in Hartford, Connecticut, put the case on hold on Monday, November 16, 2026, after both sides told the court they had reached an agreement in principle to settle. The terms of the Teva generic drug price-fixing settlement were not disclosed, and neither the company nor the Connecticut attorney general's office, which leads the states' case, immediately responded to requests for comment.
Key Points
- Teva has settled in principle the states' generic drug price-fixing case. Chief Judge Michael Shea paused the proceedings on Monday, November 16, 2026.
- The case was brought by 45 states, Washington, DC, and two US territories. The office of Connecticut Attorney General William Tong leads the litigation.
- The states said Teva raised prices significantly on about 112 generic drugs and colluded with rivals to raise prices on at least 86 of them, sometimes by more than 1,000%.
- The states alleged the scheme began in 2012, with generic drug prices skyrocketing in 2013 and 2014.
- Terms were not disclosed. The deal must still be put in writing, and Judge Shea oversees two other state generic-drug antitrust lawsuits not covered by it.
What Happened
Court records show that Chief Judge Michael Shea of the federal court in Hartford put the case on hold on Monday after lawyers for both sides told him they had reached an agreement in principle to settle. The order pauses the litigation while the parties turn their handshake deal into a written settlement for the court to review.
Reuters first reported the settlement on Monday. Teva did not immediately respond to a request for comment, and the office of Attorney General Tong did not immediately respond either.
Teva, listed in Tel Aviv and New York, is one of the world's largest makers of generic drugs, the low-cost copies of brand-name medicines that fill most prescriptions in the United States. It was one of dozens of defendants in the states' case, which accused the industry's biggest generic makers of working together, rather than competing, to keep prices high.
Background: A Decade of Litigation Over Generic Drug Prices
Generic drugs are copies of brand-name medicines that can be sold once the original patent expires. Because they are supposed to compete with each other on price, they are usually far cheaper than the brand-name version, and they account for about nine in ten prescriptions filled in the United States. Even modest rises across dozens of medicines can therefore add up to large costs for patients, insurers and government health programmes.
The states' case grew out of a wide investigation into the generic drug industry that has been running for about a decade, and related cases were grouped together under Judge Shea in Connecticut.
Teva Generic Drug Price-Fixing Settlement: What the States Alleged
The states accused Teva and the other defendants of having in 2012 "embarked on one of the most egregious and damaging price-fixing conspiracies in the history of the United States." In their account, the companies agreed to maintain their "fair share" of each generic drug market while raising prices on as many drugs as possible, carving up customers between them so that no company had to compete on price.
Prices skyrocketed in 2013 and 2014, the states said. Teva significantly raised prices on approximately 112 different generic drugs, and colluded with competitors to raise prices on at least 86 of them, sometimes by more than 1,000%, according to the states' filings. The increases fell on patients paying out of pocket, on private insurers and on public programmes such as Medicaid and Medicare.
The case named dozens of defendants alongside Teva. Judge Shea also oversees two other antitrust lawsuits brought by state attorneys general that are related to generic drugs, and neither of those cases is covered by Monday's settlement.
Reactions and Quotes
Neither side has said much in public. Teva did not immediately respond to requests for comment on Monday, and neither did the office of Attorney General Tong. The court records described so far do not say whether the settlement includes any admission of wrongdoing by Teva.
The strongest language in the case comes from the states' own complaint, which called the alleged scheme "one of the most egregious and damaging price-fixing conspiracies in the history of the United States." The states also said the companies agreed to maintain their "fair share" of each market, an arrangement that, if proved, would have removed the competition that normally keeps generic prices low.
Why It Matters
Generic drugs are the workhorses of American medicine. About nine in ten prescriptions filled in the United States are for generics, and they are the main reason many common medicines are affordable at all. If the biggest makers of those drugs were coordinating prices instead of competing, the extra cost would have been spread across millions of patients and every health plan in the country.
The settlement also matters because of its scale. A case brought by 45 states, the District of Columbia and two territories, and led by Connecticut, is one of the largest antitrust actions ever aimed at the drug industry. A settlement on undisclosed terms closes the largest single piece of that litigation.
What Happens Next
The next step is paperwork. The parties must turn their agreement in principle into a written settlement and present it to Judge Shea, who will review it before the case can be closed for good. Court filings in the coming weeks should show whether the deal involves a payment from Teva.
The litigation does not end with Teva. Dozens of other defendants were named in the states' case, and their claims continue, as do the two other generic-drug antitrust lawsuits before Judge Shea.
Frequently Asked Questions
What did the states accuse Teva of doing?
They accused Teva and dozens of other drugmakers of conspiring from 2012 to fix the prices of dozens of generic drugs, agreeing to keep their "fair share" of each market.
How many states sued Teva?
45 states, plus Washington, DC, and two US territories. Connecticut Attorney General William Tong's office leads the case.
How much did prices rise?
The states said Teva raised prices significantly on about 112 generic drugs and colluded with rivals on at least 86 of them, sometimes by more than 1,000%.
How much will Teva pay?
That is not known. The settlement terms were not disclosed, and the written agreement has not yet been filed with the court.
Does the settlement end all the generic drug cases?
No. Judge Shea oversees two other state antitrust lawsuits over generic drugs, and claims against dozens of other defendants in the Teva case continue.
More from US News Pulse: United Airlines Outage Delays 554 Flights Days After FAA Ground Stop; AI Agents Are Stealing API Keys at Industrial Scale, Amazon and FBI Warn; Senate Votes 70-27 to Advance Permitting Bill in Second Cloture Test.
Leave a Comment